RPL17 and neoplasm: Although specific blocking mAbs against PD-1 and PD-L1 have made significant impacts clinically, insufficient infiltration levels of effector T cells in some solid tumour types or different expression levels of PD-L1 in tumour tissues may negatively affect the treatment efficiency of these immune checkpoint blockers [161, 162].